Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark A Applebaum

Showing results (41-50 of 61) with videos related to

Pageof 7
Sort By:
Cancers|May 4, 2026
Histotripsy-Initiated Immune Response Synergizes with Chemotherapy in a Neuroblastoma Murine ModelNatalia Antonides-Jensen, Muskan Singh, Yuqing Xue, et al.
Journal of the National Cancer Institute|November 9, 2017
Evaluation of Genetic Predisposition for MYCN-Amplified NeuroblastomaEric A Hungate, Mark A Applebaum, Andrew D Skol, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|April 13, 2023
Diffuse Pediatric-type High-grade Glioma Arising in an Ovarian Mature Cystic TeratomaLena Elmuti, Julia Amundson, Elise Oberman, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 11, 2024
Targeting DTX2/UFD1-mediated FTO degradation to regulate antitumor immunityYan-Hong Cui, Jiangbo Wei, Hao Fan, et al.
Clinical and Translational Science|June 11, 2026
A Bayesian-Based Integrative Bioinformatics Analysis Nominates Oncogenic Drivers in NeuroblastomaLin Xu, Arhanti Sadanand, Evan W Neczypor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2020
Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG ProjectElizabeth Sokol, Ami V Desai, Mark A Applebaum, et al.
Pediatric Blood & Cancer|August 29, 2025
Outcomes for Patients Aged 12-18 Months With Metastatic MYCN Non-Amplified Neuroblastoma and Unfavorable Biologic Features ("Mixed Biology Toddlers"): A Report From the International Neuroblastoma Risk Group (INRG) ProjectMallory R Taylor, James R Anderson, Julie R Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2020
Reply to K. Beiske et alElizabeth Sokol, Ami V Desai, Mark A Applebaum, et al.
Oncotarget|October 22, 2016
Integrative genomics reveals hypoxia inducible genes that are associated with a poor prognosis in neuroblastoma patientsMark A Applebaum, Aashish R Jha, Clara Kao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2015
Advances in Risk Classification and Treatment Strategies for NeuroblastomaNavin R Pinto, Mark A Applebaum, Samuel L Volchenboum, et al.
Pageof 7

Showing results (41-50 of 61) with videos related to

Sort By:
Pageof 7
Cancers|May 4, 2026
Histotripsy-Initiated Immune Response Synergizes with Chemotherapy in a Neuroblastoma Murine ModelNatalia Antonides-Jensen, Muskan Singh, Yuqing Xue, et al.
Journal of the National Cancer Institute|November 9, 2017
Evaluation of Genetic Predisposition for MYCN-Amplified NeuroblastomaEric A Hungate, Mark A Applebaum, Andrew D Skol, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|April 13, 2023
Diffuse Pediatric-type High-grade Glioma Arising in an Ovarian Mature Cystic TeratomaLena Elmuti, Julia Amundson, Elise Oberman, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 11, 2024
Targeting DTX2/UFD1-mediated FTO degradation to regulate antitumor immunityYan-Hong Cui, Jiangbo Wei, Hao Fan, et al.
Clinical and Translational Science|June 11, 2026
A Bayesian-Based Integrative Bioinformatics Analysis Nominates Oncogenic Drivers in NeuroblastomaLin Xu, Arhanti Sadanand, Evan W Neczypor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2020
Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG ProjectElizabeth Sokol, Ami V Desai, Mark A Applebaum, et al.
Pediatric Blood & Cancer|August 29, 2025
Outcomes for Patients Aged 12-18 Months With Metastatic MYCN Non-Amplified Neuroblastoma and Unfavorable Biologic Features ("Mixed Biology Toddlers"): A Report From the International Neuroblastoma Risk Group (INRG) ProjectMallory R Taylor, James R Anderson, Julie R Park, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2020
Reply to K. Beiske et alElizabeth Sokol, Ami V Desai, Mark A Applebaum, et al.
Oncotarget|October 22, 2016
Integrative genomics reveals hypoxia inducible genes that are associated with a poor prognosis in neuroblastoma patientsMark A Applebaum, Aashish R Jha, Clara Kao, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 26, 2015
Advances in Risk Classification and Treatment Strategies for NeuroblastomaNavin R Pinto, Mark A Applebaum, Samuel L Volchenboum, et al.
Pageof 7